Tersera Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Tersera Therapeutics (Deerfield, IL): 4 reconciled FDA prescription therapies (2.0% 2025 to 2030 cliff risk), $26.8M 2024 CMS Part D & Medicaid spend, and 25 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterDeerfield, IL
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure2.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$26.8M
2024 Medicare Part D Spend$25.4M
2024 Medicaid Spend$1.4M
California HCAI SB 17 Filings25 WAC filings (max 48.9% 2-yr change)